Drug Database
Back to search

Iceland· IS-IS/1/17/046/01

Cleye

A naphazoline product containing naphazolinum inn hýdróklóríð, registered in Iceland by Elara Pharmaservices Europe Limited. The same ATC class is registered in 8 of our 19 countries.

ATC S01GA01

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedCleyeATCS01GA01REGISTER NO.IS-IS/1/17/046/01PACKS LISTED0CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about naphazolinum inn hýdróklóríðAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Naphazoline is registered in 8 of 19 countries.

Countries holding a registration under ATC S01GA01 (naphazoline), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 4 of them publish a price we can compare per daily dose
Search naphazoline products by name

Naphazoline · ATC S01GA01

8 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Norwayprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Naphazolinum INN hýdróklóríð
Manufacturer
Elara Pharmaservices Europe Limited
Country
Iceland (IS)
ATC code
S01GA01
ATC class
Naphazoline
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

53 interactions on record for naphazoline.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check naphazoline against other medicinesHow interaction checks work

Naphazoline · interactions on record

53 records

  • 7 severe
  • 46 moderate

Most severe, free to view

  • MethylergometrineG02AB01severe
  • ErgometrineG02AB03severe
  • DihydroergotamineN02CA01severe
  • ErgotamineN02CA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Naphazoline in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All naphazoline products

Authorised across Europe · EMA

The same active substance is authorised in 17 EEA countries. Names it is sold under:

  • Austria · Aconex, Coldan
  • Czechia · Sanorin
  • Germany · Duraultra N Sine, Rhinex Nasenspray Mit Naphazolin
  • Denmark · Cleareyes
  • Spain · Centilux
  • Finland · Cleari
  • United Kingdom (Northern Ireland) · Clear Eyes, Murine Irritation & Redness Relief
  • Croatia · Nazol, Proculin
  • Hungary · Iridina Due
  • Ireland · Murine Irritation & Redness Relief
  • Italy · Brunizina, Collirio Alfa Decongestionante
  • Latvia · Naphthyzinum
  • Norway · Cleye
  • Romania · Rinofug
  • Sweden · Cleari
  • Slovenia · Proalkalin
  • Slovakia · Sanorin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2da73830-2600-4793-925b-a4cdcdd10a52
GET /v1/drugs/2da73830-2600-4793-925b-a4cdcdd10a52?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Augndropar, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "S01GA01",
  "marketed": true,
  "strength": "0,12 mg/ml",
  "ma_number": "IS/1/17/046/01",
  "substance": "Naphazolinum INN hýdróklóríð",
  "other_info": null,
  "legal_status": "(L) Ekki lyfseðilsskylt",
  "ma_issued_serial": "42914"
}
API referenceMCP serverPlans

See everything about naphazoline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console